4425-23-4
Chemical Structure
RLX
Synonym(s): PD 139530
- CAS No.: 4425-23-4
- Formula:C13H14N2O
- Molecular Weight:214.26
IUPAC Name: 7,8,9,10-tetrahydroazepino[2,1-b]quinazolin-12(6H)-one
InChIKey: HTLIIBRHXAULMB-UHFFFAOYSA-N
SMILES: O=C1N2C(CCCCC2)=NC3=C1C=CC=C3
Biological Activity: RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
RLX | RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Keywords
